A bivalent recombinant vaccine: a promising strategy against both SARS-CoV-2 variants and wild type of the virus.
A bivalent recombinant vaccine: a promising strategy against both SARS-CoV-2 variants and wild type of the virus.
复制标题
DOI：
10.1038/s41392-021-00691-4
复制
发表时间：
2021-07-17
影响因子：
39.3
通讯作者：
Wang J
中科院分区：
文献类型：
--
作者：
Wang J
他等人最近在《医学通讯》杂志上发表了一项研究。1.介绍SARS冠状病毒(SARS-CoV-2)野生型和变异型S1亚基蛋白疫苗(S1-WT和S1-Mut)，以评价其免疫保护效果。该团队进一步分析了由S1-WT和S1-Mut组成的双价疫苗对SARS-CoV-2和突变株的中和活性，以探索一种通用的保护性疫苗。自SARS-CoV-2大流行以来，冠状病毒病2019年(新冠肺炎)仍然是一个威胁生命的全球性问题。迄今为止，SARS-CoV-2在世界许多地区的传播仍未得到控制。截至2021年5月4日，SARS-CoV-2已导致超过1.53亿新冠肺炎患者和320万人死亡，以及沉重的经济负担和不堪重负的卫生系统。令人欣慰的是，重组中和抗体和各种疫苗的发展有助于控制新冠肺炎大流行。然而，据报道，越来越多的SARS-CoV-2变种具有更强的传染性/传播性，并增强了规避药物和免疫控制的能力，这给控制大流行带来了新的挑战。2SARS-CoV-2和变异株的通用冠状病毒疫苗是基于新出现的变异株而提出的，因为现有疫苗对变异株的保护作用减弱。据报道，在南非的临床研究中，Novavax NVX-CoV2373亚单位疫苗的疗效从89.3%下降到49.4%。3ChAdOx1黑猩猩腺病毒载体疫苗(AZD1222)的免疫保护效果下降更为显著，对B.1.351的免疫效力仅为10.4%。4确定重组S1-WT和S1-Mut蛋白疫苗对SARS-CoV-2野生型和变异型的交叉保护作用。1选择了目前SARS-CoV-2主要变异株(B.1.1)中出现的K417N、E484K、N501Y和D614G等毒株的S1-WT和S1-Mut。7、B.1.351和P.1)构建重组蛋白疫苗，发现S1-WT免疫小鼠血清中rBD-WT特异性抗体的几何平均滴度为8.65×10~6，而rBD-Mut抗体的几何平均滴度为1.08×10~6。此外，S1-Mut免疫小鼠血清中S1-Mut抗体的GMT显著高于S1-WT免疫小鼠(1.08×106vs2.7×105)，表明S1-WT蛋白可激发更强的S1-WT和RBD-WT特异性抗体应答，且S1-Mut蛋白可诱导突变型S1和RBD抗体应答。此外，重组S1-WT或S1-Mut蛋白诱导的中和抗体对ACE2与RBD-WT或RBD-Mut的结合均有较强的阻断作用。此外，血清
A recent study published in Medcomm by He et al. 1 introduced protein subunit vaccines with wild-type and mutant S1 subunit (S1-WT and S1-Mut) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to evaluate their immunoprotective efficacy. The team further analyzed the neutralization activity of bivalent vaccine composed of S1-WT and S1-Mut for SARS-CoV-2 and mutant strains to explore a universal protective vaccine. The coronavirus disease 2019 (COVID-19) is still a lifethreatening global problem since the SARS-CoV-2 pandemic. To date, SARS-CoV-2 transmission is still uncontrolled in many parts of the world. As of May 4, 2021, SARS-CoV-2 has caused more than 153 million COVID-19 patients and 3.2 million deaths as well as heavy economic burden and overburdened health systems. Comfortingly, the development of recombinant neutralization antibodies and kinds of vaccines contributes to the control of the COVID-19 pandemic. However, a growing number of SARS-CoV-2 variants with enhanced infectivity/transmissibility and increased ability to circumvent drug and immune control have been reported, which brings about new challenges to control the pandemic. 2A universal coronavirus vaccine against both SARS-CoV-2 and mutant strains has been called for based on the emerging variants because of the decreased protective role of existing vaccines against mutant strains. As reported, the Novavax NVX-CoV2373 subunit vaccine showed a reduced efficacy from 89.3% to 49.4% in clinical studies in South Africa. 3 Moreover, the protective efficacy of ChAdOx1 chimpanzee adenoviral vectored vaccine (AZD1222) declined more significantly, and the vaccine efficacy against B. 1.351 was only 10.4%. 4 To determine the cross-protection of recombinant S1-WT and S1-Mut protein vaccine against wild-type and mutant SARS-CoV-2, He et al. 1 chose S1-WT and S1-Mut including K417N, E484K, N501Y and D614G that appear in the current main SARS-CoV-2 mutant strains (B. 1.1. 7, B. 1.351, and P. 1) to formulate the recombinant protein vaccine, and they discovered that the geometric mean titers (GMT) of RBD-WT specific antibodies in serum from S1-WT immunized mice was 8.65× 106 while the GMT of RBD-Mut antibodies was 1.08× 106. Besides, the GMT of S1-Mut antibodies in serum from S1-Mut immunized mice was much higher than that of S1-WT immunized mice (1.08× 106 vs 2.7× 105), indicating that S1-WT protein stimulates stronger S1-WT and RBD-WT specific antibody responses, and S1-Mut protein could induce mutant S1 and RBD antibody responses. In addition, the neutralization antibodies induced by recombinant S1-WT or S1-Mut protein displayed strong blockade on the binding between ACE2 and RBD-WT or RBD-Mut, respectively. Moreover, the sera
登录
查看更多内容
DOI：
10.1126/science.abc4730
发表时间：
2020-09-25
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Gu H;Chen Q;Yang G;He L;Fan H;Deng YQ;Wang Y;Teng Y;Zhao Z;Cui Y;Li Y;Li XF;Li J;Zhang NN;Yang X;Chen S;Guo Y;Zhao G;Wang X;Luo DY;Wang H;Yang X;Li Y;Han G;He Y;Zhou X;Geng S;Sheng X;Jiang S;Sun S;Qin CF;Zhou Y
通讯作者：
Zhou Y
DOI：
10.1056/nejmoa2102214
发表时间：
2021-05-20
期刊：
The New England journal of medicine
影响因子：
--
作者：
Madhi SA;Baillie V;Cutland CL;Voysey M;Koen AL;Fairlie L;Padayachee SD;Dheda K;Barnabas SL;Bhorat QE;Briner C;Kwatra G;Ahmed K;Aley P;Bhikha S;Bhiman JN;Bhorat AE;du Plessis J;Esmail A;Groenewald M;Horne E;Hwa SH;Jose A;Lambe T;Laubscher M;Malahleha M;Masenya M;Masilela M;McKenzie S;Molapo K;Moultrie A;Oelofse S;Patel F;Pillay S;Rhead S;Rodel H;Rossouw L;Taoushanis C;Tegally H;Thombrayil A;van Eck S;Wibmer CK;Durham NM;Kelly EJ;Villafana TL;Gilbert S;Pollard AJ;de Oliveira T;Moore PL;Sigal A;Izu A;NGS-SA Group;Wits-VIDA COVID Group
通讯作者：
Wits-VIDA COVID Group
影响因子：
64.8
作者：
通讯作者：
--
影响因子：
4
作者：
Ni Y;Alu A;Lei H;Wang Y;Wu M;Wei X
通讯作者：
Wei X
影响因子：
9.9
作者：
He C;Yang J;He X;Hong W;Lei H;Chen Z;Shen G;Yang L;Li J;Wang Z;Song X;Wang W;Lu G;Wei X
通讯作者：
Wei X